Join the department of epidemiology and biostatistics for a brown bag seminar by the Cancer Prevention and Control Program Colloquium on Monday, December 5 from 1-2 p.m. in Discovery 331 for a discussion on Fluoroquinolone-associated Neuropsychiatric Toxicity, Disability, Suicide, and Genetics: A Review from SONAR by Dr. Charles Bennett.
Charles L. Bennett, MD PhD MPP, is the SmartState Chair and Director SmartState Center for Medication Safety and Efficacy. he is the Josie M. Fletcher Professor in the Department of Clinical Pharmacy and Outcomes Sciences University of South Carolina College of Pharmacy.
Dr. Bennett is an internationally recognized leader in the field of pharmacovigilance and directs the only state funded pharmaceutical safety program in the nation. His current research is focusing on oncology biosimilars. He has identified fatal and near fatal side effects of > 30 billion dollar pharmaceuticalsincluding epoetin and pure red cell aplasia, peginesatide and fatal anaphylaxis, epoetin and darbepoetin associated tumor progression, ritixumab, brentuximab vedotin, and ibrutinib-associated progressive multifocal leukoencephalopathy, ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura, gemtuzumab ozogamycin-associated sinusoidal obstructive syndrome, and gadolinium-associated nephrogenic systemic fibrosis. His most recent safety evaluation is on ciprofloxacin- and Levaquinassociated psychiatric toxicity, which was reviewed at a November 5 FDA Advisory Committee hearing where the vote was 21-0 in support of Dr. Bennett’s findings. Current funding includes: National Institutes of Health (Grant No. R01CA16509), the American Cancer Society (IRG-13-043-01), and the South Carolina SmartState Program.